What We're Reading: Page 167
Industry reads hand-picked by our editors
Feb 25, 2021
-
BioCentury
Democratic opposition could sink Woodcock’s chances to be nominated as permanent FDA commissioner
-
STAT
GSK's Covid-19 drug falls short in trial, but may benefit older patients
-
Boston Business Journal
Cellarity, Flagship startup that aims to treat 'any disease,' raises $123M
-
Reuters
Regeneron to stop giving placebo in COVID-19 drug trial after 'clear efficacy'
Feb 24, 2021
Feb 23, 2021
-
NPR
History Repeats Itself: COVID-19 Vaccine Inequities Echo HIV Crisis
-
The New York Times
Researchers Halt Trials of Promising Sickle Cell Treatment
-
The Wall Street Journal
To Make More Covid-19 Vaccines, Rival Drugmakers Team Up
Feb 22, 2021
-
The New York Times
Who Will Be the Next F.D.A. Chief?
-
FiercePharma
AbbVie, Eli Lilly lead Big Pharma's 2020 market cap growth as Merck, Gilead lag
-
NPR
Price Check: Nations Pay Wildly Different Prices For Vaccines
-
Endpoints News
Otonomy's resurrected ear drug is now dead again — and investors aren’t hanging around
Feb 19, 2021
-
Bloomberg
A U.S. Vaccine Surge Is Coming, With Millions of Doses Promised
-
The New York Times
Clinical Trials Are Moving Out of the Lab and Into People’s Homes
-
The Wall Street Journal
IBM Explores Sale of IBM Watson Health
-
FierceBiotech
In conversation with John Leonard, CEO of Intellia
Feb 18, 2021
-
The Washington Post
Biden picks Chiquita Brooks-LaSure to run Medicare, Medicaid
-
Evaluate Vantage
The reckoning begins for biotech-focused Spacs
-
STAT
Covid crushed in-person pharma sales. Tech is pitching itself as a solution
-
Financial Times
Russia’s Covid vaccine faces global production hurdles
Feb 17, 2021
-
The Wall Street Journal
Insiders at Covid-19 Vaccine Makers Sold Nearly $500 Million of Stock Last Year
-
Endpoints News
After four decades, one researcher's radical HIV cure finally gets its shot
-
The BMJ
Why did a German newspaper insist the Oxford AstraZeneca vaccine was inefficacious for older people—without evidence?
-
Raleigh News & Observer
Humacyte goes public via SPAC for deal valued at $1.1B
Previous
